Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Gains from Investment Securities: 2017-2024

Historic Gains from Investment Securities for Mereo BioPharma Group (MREO) over the last 8 years, with Dec 2024 value amounting to -$1.8 million.

  • Mereo BioPharma Group's Gains from Investment Securities fell 432.20% to -$196,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 million, marking a year-over-year decrease of 783.80%. This contributed to the annual value of -$1.8 million for FY2024, which is 30.89% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Gains from Investment Securities stood at -$1.8 million for FY2024, which was down 30.89% from -$1.3 million recorded in FY2023.
  • Mereo BioPharma Group's 5-year Gains from Investment Securities high stood at $14.0 million for FY2020, and its period low was -$9.3 million during FY2022.
  • Its 3-year average for Gains from Investment Securities is -$4.1 million, with a median of -$1.8 million in 2024.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first spiked by 1,149.63% in 2020, then plummeted by 6,196.17% in 2022.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Gains from Investment Securities stood at $14.0 million in 2020, then slumped by 98.91% to $152,325 in 2021, then tumbled by 6,196.17% to -$9.3 million in 2022, then spiked by 85.60% to -$1.3 million in 2023, then slumped by 30.89% to -$1.8 million in 2024.